Simon Taylor-Robinson joined the Hammersmith Hospital MR Unit in 1992 and was made a permanent member of staff at Imperial College London in 1997. He became Professor of Translational Medicine in 2007. He is a career hepatologist with clinical appointments as a consultant at Imperial College Healthcare Trust in London (St Mary’s and Hammersmith Hospitals). Over the past 25 years, he has investigated pathogenic mechanisms in chronic liver disease using a combination of imaging techniques, MRS and mass spectroscopy. He has over 300 publications currently. He has strong connections with Africa, having forged research partnerships through European Framework 7 with clinical and research groups in Nigeria, Senegal and Gambia. He has visited many African countries in research and clinical capacities, including South Sudan, Sudan and Kenya. He has developed links with Khon Kaen University in Thailand over the past decade to investigate novel urinary biomarkers of cancer in patients with cholangiocarcinoma caused by the liver fluke, Opisthorchis viverrini. In June 1999, he received a MRC Career Establishment grant for the study of liver fibrosis. This generated industrial sponsorship from Pfizer and GSK. He holds grants from the MRC (one jointly with Newcastle, Cambridge and Birmingham Universities on primary biliary cirrhosis (PBC)), the National Institute for Health Research and the Wellcome Trust. He is clinically responsible for patients with liver disease at St. Mary’s Hospital (Imperial College Healthcare Trust) and is currently Director of the Imperial Clinical Research Facility, which has access to the largest cohort of viral hepatitis patients for study in Europe, in addition to well characterised patients with fatty liver disease and PBC. He was awarded the Sir Francis Avery Jones Gold Medal by the British Society of Gastroenterology in 1999, the Linacre Lectureship of the Royal College of Physicians of London in September 2000 and the Blumberg Prize in 2018.